Sanofi Dives Back Into ADCs With Seagen Pact
Deal Value Under Wraps
Despite underwhelming sales for some cancer products and problems within the pipeline, Sanofi is forging ahead with an agreement for up to three ADCs with Seagen.
You may also be interested in...
The Busiest Dealmakers Of 2022
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Europe’s Big Pharma Players Begin Tricky 2022 In Style
Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.
Dupixent Drives Sanofi Growth Again Amid Pipeline Renewal
The major’s atopic dermatitis blockbuster made more than €1.6bn this quarter, but the firm’s R&D costs are rising as it attempts to add some fresh blood to its stagnating pipeline.